From denial to resolution. Step by step.

AuthAnnie turns the messy, manual denial appeal process into a structured, evidence-driven workflow. Here's how.

01

A denial arrives

When a claim is denied, the denial details — reason code, payer, drug, patient — enter the AuthAnnie pipeline. Whether it's a CO-4, a PR-204, or any other code, the system knows what it's dealing with.

AuthAnnie categorizes the denial by type, payer, and therapeutic area. It identifies the specific criteria the payer is using and maps it against the patient's clinical record.

app.authannie.com/dashboard
Active Denials
24
+3 this week
Appeals Won
89%
+5% vs last quarter
Revenue Recovered
$142K
This quarter
Avg Resolution
4.2d
Down from 11 days
Denial Pipeline
New (6)In Review (10)Appeal Sent (14)Won (8)
Recent Denials
CO-4Evenity
Appeal Ready
CO-16Prolia
In Review
PR-204Tymlos
New
02

Clinical evidence is assembled

AuthAnnie pulls the relevant clinical data: diagnosis codes, lab results (T-scores, blood work), imaging studies, prior treatment history, and any other data points that support medical necessity.

Each data point is extracted with a confidence score. The system identifies which clinical guidelines apply — ASBMR for osteoporosis, NCCN for oncology, ACR for rheumatology — and maps the patient's data against the guideline criteria.

app.authannie.com/denials/DEN-2024-0847/extraction
Clinical Intelligence Extraction98% confidence
Diagnosis
Postmenopausal osteoporosis (M81.0)
99%
Drug Denied
Evenity (romosozumab-aqqg) 210mg SC monthly
99%
Denial Reason
CO-4: Not medically necessary per plan criteria
97%
Prior Therapy
Alendronate 70mg weekly x 3 years (discontinued 2023-09)
94%
Key Lab
DXA lumbar T-score: -2.8 (2024-01-15)
98%
Risk Score
FRAX 10yr major: 22%, hip: 4.8%
96%
Guideline Match Found
ASBMR 2020: Romosozumab recommended for postmenopausal women with T-score ≤ -2.5 and prior bisphosphonate use with continued fracture risk.
03

An appeal is generated

A tailored appeal letter is produced — not a generic template, but a letter that addresses the specific denial reason with the patient's specific clinical evidence and the relevant guideline citations.

The appeal is structured to meet payer expectations: patient demographics, clinical summary, guideline references, and a clear argument for medical necessity. Your team reviews, edits if needed, and submits.

app.authannie.com/denials/DEN-2024-0847
DEN-2024-0847
Evenity (romosozumab-aqqg)
Patient: M. Chen • Provider: Dr. Carpenter
Appeal Ready
Clinical Evidence Assembled
T-score: -2.8 lumbar spine (DXA 2024-01-15)
FRAX 10yr major fracture risk: 22%
Prior bisphosphonate therapy documented (3 years)
ASBMR guideline citation attached
Timeline
Denial receivedMar 2
Clinical data extractedMar 2
Appeal letter generatedMar 3
Submitted to UHCPending
04

Outcomes are tracked

After submission, AuthAnnie tracks the appeal status through resolution. Win rates, turnaround times, and revenue recovered are reported in real time.

Over time, your data reveals patterns — which payers deny most frequently, which denial codes are easiest to overturn, and where your practice is losing the most revenue. This data drives smarter payer strategy.

app.authannie.com/analytics
Active Denials
24
+3 this week
Appeals Won
89%
+5% vs last quarter
Revenue Recovered
$142K
This quarter
Avg Resolution
4.2d
Down from 11 days
Denial Pipeline
New (6)In Review (10)Appeal Sent (14)Won (8)
Recent Denials
CO-4Evenity
Appeal Ready
CO-16Prolia
In Review
PR-204Tymlos
New

Ready to see it in action?

Request a demo and we'll walk through your practice's specific scenario.

Request a Demo